Venclexta Tablets 50 mg & 100 mg | Venetoclax

Product Introduction

Venclexta Tablets contain Venetoclax, a targeted anticancer medicine belonging to the BCL-2 inhibitor class. It is used in specific treatment regimens for certain blood cancers, including chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and selected cases of acute myeloid leukaemia (AML).

Venclexta 50 mg and 100 mg are oral tablet strengths. Treatment must be prescribed and monitored by a qualified oncologist according to the approved product information and the patient's medical condition.

Product Specifications

Specification

Details

Brand name

Venclexta

Generic name

Venetoclax

Strengths

50 mg and 100 mg

Dosage form

Tablets

Route of administration

Oral

Therapeutic category

Oncology – BCL-2 inhibitor

Manufacturer

Verify against actual product packaging

Pack size

As per available product presentation

Uses of Venclexta Tablets

Venetoclax is used in approved treatment regimens for eligible adults with CLL or SLL. It is also used in combination with medicines such as azacitidine, decitabine or low-dose cytarabine for certain adults with newly diagnosed AML.

The approved indications and treatment combinations can vary between countries. Healthcare professionals should consult the relevant local prescribing information before prescribing or dispensing this medicine.

How Does Venetoclax Work?

Venetoclax blocks the BCL-2 protein, which helps certain cancer cells survive. By inhibiting this protein, the medicine can promote cancer-cell death in susceptible blood cancers.

Dosage and Administration

Venclexta should be taken exactly as prescribed by an oncologist. The dosage and treatment schedule depend on the indication, combination therapy, laboratory results and individual patient factors.

For certain indications, treatment begins with a gradual dose escalation to reduce the risk of tumour lysis syndrome (TLS). Patients should not change their dose or treatment schedule without medical advice.

Possible Side Effects

Possible adverse effects include:

Neutropenia and other low blood-cell counts.

Anaemia and low platelet counts.

Nausea, diarrhoea or constipation.

Fatigue and weakness.

Fever and respiratory infections.

Vomiting.

Serious risks include tumour lysis syndrome, severe infections and significant blood-count abnormalities. Seek urgent medical attention for fever, reduced urination, severe weakness, confusion or an irregular heartbeat.

Important Warnings and Precautions

Tumour Lysis Syndrome (TLS): Rapid cancer-cell breakdown can cause dangerous changes in blood chemistry and kidney complications. Risk assessment, hydration, preventive treatment and laboratory monitoring are essential.

Neutropenia and infections: Blood counts should be monitored, and signs of infection require prompt medical assessment.

Drug interactions: Medicines that affect CYP3A or P-glycoprotein can change venetoclax exposure. Inform the treating doctor about all medicines and supplements.

Pregnancy and breastfeeding: Venetoclax may cause embryo-fetal harm. Pregnancy prevention and breastfeeding precautions should follow the approved prescribing information.

Product Availability & Export Enquiries

Cordium Pharmaceuticals Pvt. Ltd. welcomes enquiries from authorised pharmaceutical distributors, importers and eligible institutional buyers regarding Venclexta Tablets 50 mg and 100 mg.

Contact our team for product availability, commercial quotations, product specifications and relevant export documentation. All supplies are subject to verified availability, applicable product registrations and destination-country import regulations.

Frequently Asked Questions

1. What is Venclexta used for?

Venetoclax is used in certain approved treatment regimens for CLL, SLL and selected cases of AML.

2. What is the difference between 50 mg and 100 mg tablets?

They contain different amounts of venetoclax. The prescribed strength and number of tablets depend on the oncologist's treatment plan.

3. Is Venclexta a chemotherapy medicine?

Venetoclax is a targeted anticancer medicine classified as a BCL-2 inhibitor.

4. What is its most important safety risk?

Tumour lysis syndrome is a major risk, particularly when treatment is initiated. Specialist supervision and monitoring are essential.

5. How can buyers enquire about Venclexta?

Authorised buyers can contact Cordium Pharmaceuticals Pvt. Ltd. for product and export enquiries, subject to applicable regulations.

Medical Disclaimer

This page provides general product information and pharmaceutical trade details only. It is not a substitute for medical advice or approved prescribing information. Venetoclax must be used under qualified medical supervision.